PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
14.01%
Revenue growth 1.25-1.5x META's 12.29%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
17.43%
Gross profit growth 1.25-1.5x META's 12.33%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
11.24%
EBIT growth similar to META's 10.27%. Walter Schloss might infer both firms share similar operational efficiencies.
11.24%
Operating income growth at 50-75% of META's 16.44%. Martin Whitman would doubt the firm’s ability to compete efficiently.
11.19%
Net income growth 1.25-1.5x META's 10.17%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
9.43%
EPS growth similar to META's 10.47%. Walter Schloss would assume both have parallel share structures and profit trends.
10.74%
Similar diluted EPS growth to META's 11.04%. Walter Schloss might see standard sector or cyclical influences on both firms.
1.63%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.85%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
3.54%
OCF growth at 50-75% of META's 6.39%. Martin Whitman would question if the firm lags in monetizing sales effectively.
-24.18%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
920.42%
10Y revenue/share CAGR at 75-90% of META's 1223.16%. Bill Ackman would press for new markets or product lines to narrow the gap.
920.42%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
920.42%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
976.04%
Below 50% of META's 2770.56%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
976.04%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
976.04%
3Y net income/share CAGR above 1.5x META's 194.47%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.12%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
110.13%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
118.83%
BV/share growth above 1.5x META's 5.80%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-96.56%
We’re deleveraging while META stands at 0.08%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
58.42%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
12.88%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.